Home  »  Companies   »  Abbott Laboratories (NYSE: ABT) Up 0.81%: This Is ...

Abbott Laboratories (NYSE: ABT) Up 0.81%: This Is What Analysts Now Expect

Abbott Laboratories (NYSE:ABT) shares, rose in value on Thursday, June 23, with the stock price up by 0.81% to the previous day’s close as strong demand from buyers drove the stock to $106.29.

Actively observing the price movement in the recent trading, the stock is buoying the session at $105.44, falling within a range of $103.29 and $106.58. The value of beta (5-year monthly) is 0.73 whereas the PE ratio is 24.34 over 12-month period. Referring to stock’s 52-week performance, its high was $142.60, and the low was $101.24. On the whole, ABT has fluctuated by -6.89% over the past month.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


With the market capitalization of Abbott Laboratories currently standing at about $183.79 billion, investors are eagerly awaiting this quarter’s results, scheduled for Apr 18, 2022 – Apr 22, 2022. The company’s Forward Dividend Ratio is 1.88, with its dividend yield at 1.78%. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be $1.12, which is expected to increase to $1.05 for fiscal year $4.87 and then to about $4.92 by fiscal year 2023. Data indicates that the EPS growth is expected to be -6.50% in 2023, while the next year’s EPS growth is forecast to be 1.00%.

Analysts have estimated the company’s revenue for the quarter at $10.23 billion, with a low estimate of $9.59 billion and a high estimate of $10.52 billion. According to the average forecast, sales growth in current quarter could jump up 5.50%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2023, the company’s y-o-y revenues would reach $41.58 billion, representing a decrease of -3.50% from the revenues reported in the last year’s results.

Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that ABT’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium term indicators have put the stock in the category of 100% Sell while long term indicators on average have been pointing out that it is a 100% Sell.

21 analyst(s) have assigned their ratings of the stock’s forecast evaluation on a scale of 1.00-5.00 to indicate a strong buy to a strong sell recommendation. The stock is rated as a Hold by 1 analyst(s), 13 recommend it as a Buy and 5 called the ABT stock Overweight. In the meantime, 1 analyst(s) believe the stock as Underweight and 1 think it is a Sell. Thus, investors eager to increase their holdings of the company’s stock will have an opportunity to do so as the average rating for the stock is Overweight.

The stock’s technical analysis shows that the PEG ratio is about 1.93, with the price of ABT currently trading nearly -4.40% and -6.24% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 41.81, while the 7-day volatility ratio is showing 2.40% which for the 30-day chart, stands at 2.37%. Furthermore, Abbott Laboratories (ABT)’s beta value is 0.77, and its average true range (ATR) is 3.04. The company’s stock has been forecasted to trade at an average price of $138.36 over the course of the next 52 weeks, with a low of $111.00 and a high of $150.00. Based on these price targets, the low is -4.43% off current price, whereas the price has to move -41.12% to reach the yearly target high. Additionally, analysts’ median price of $141.00 is likely to be welcomed by investors because it represents a decrease of -32.66% from the current levels.

A comparison of Abbott Laboratories (ABT) with its peers suggests the former has fared considerably weaker in the market. ABT showed an intraday change of 0.81% in today’s session so far, and over the past year, it shrunk by -4.97%%. In comparison, Johnson & Johnson (JNJ) has moved higher at 1.68% today and is up 7.41% over the past 12 months. On the other hand, the price of Rogers Corporation (ROG) has risen 0.25% today. The stock, however, is off 34.48% from where it was a year ago. The PE ratio stands at 24.34 for Abbott Laboratories, compared to 23.67 for Johnson & Johnson, and 52.48 for Rogers Corporation. Other than that, the overall performance of the S&P 500 during the today’s session so far shows that it gained 0.86%. Meanwhile, the Dow Jones Industrial Improved by 0.53%.

Data on historical trading for Abbott Laboratories (NYSE:ABT) indicates that the trading volumes over the past 3 months, they’ve averaged 5.33 million. According to company’s latest data on outstanding shares, there are 1.76 billion shares outstanding.

Nearly 0.50% of Abbott Laboratories’s shares belong to company insiders and institutional investors own 75.40% of the company’s shares. The stock has fallen by -25.08% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ABT stock heading into the next quarter.

Leave a Comment

Your email address will not be published.

Related Videos

Related Posts